NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 109)
Posted On: 10/20/2023 4:49:52 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Committed to R&D, Eyeing Excellent Opportunities
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory endeavors. “In the three months ended May 31, 2023 (‘Q3 2023’), for example, the company increased its R&D expenses 118% year over year to $1.64 million from $752,095 in Q3 2022. A recent Zacks Investment Research report attributed this expenditure to Lexaria’s multiple DehydraTECH investigational research programs then underway, including analysis and execution of hypertension, nicotine and diabetes studies. The report also lauded the company’s efficient use of capital, which allowed its R&D activities to expand into new preclinical work, including hormone therapy and dementia,” a recent article reads. “While still at an early stage, these programs could be excellent partnership opportunities that will support further growth and potentially provide growth capital,” reads the report. “Research efforts around these indications help further characterize DehydraTECH-CBD and its advantages compared with traditional delivery methods.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory endeavors. “In the three months ended May 31, 2023 (‘Q3 2023’), for example, the company increased its R&D expenses 118% year over year to $1.64 million from $752,095 in Q3 2022. A recent Zacks Investment Research report attributed this expenditure to Lexaria’s multiple DehydraTECH investigational research programs then underway, including analysis and execution of hypertension, nicotine and diabetes studies. The report also lauded the company’s efficient use of capital, which allowed its R&D activities to expand into new preclinical work, including hormone therapy and dementia,” a recent article reads. “While still at an early stage, these programs could be excellent partnership opportunities that will support further growth and potentially provide growth capital,” reads the report. “Research efforts around these indications help further characterize DehydraTECH-CBD and its advantages compared with traditional delivery methods.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼